Background As recurrences after treatment for differentiated thyroid cancer can occur many years after thyroidectomy, periodic monitoring of serum thyroglobulin (Tg) levels is performed in these patients. However, autoantibodies that can interfere with Tg immunoassays occur in the blood of approximately 25% of these patients. Several earlier reports suggest that measuring Tg mRNA by reverse-transcriptase polymerase chain reaction (RT-PCR) could be of value, especially in patients with Tg autoantibodies.
Introduction
Patients treated for di¡erentiated thyroid cancer are at risk from recurrence even many years after primary treatment. Therefore, periodic monitoring of serum thyroglobulin (Tg) levels is performed. 1 Tg is a thyroid-speci¢c protein of approximately 660 kDa, encoded by a gene on 8q24 containing over 42 exons. Two identical subunits make up the mature Tg protein that is a precursor in the biosynthesis of thyroid hormones within the thyroid gland. In the absence of a thyroid, this protein should not be detectable in blood, making it an excellent marker for recurrence after total thyroidectomy. However, autoantibodies that can interfere with Tg immunoassays occur in the blood of approximately 25% of these patients. 2 Therefore, e¡orts are directed towards developing assays that are not in£uenced by autoantibodies. Measuring Tg mRNA in peripheral blood by reverse-transcriptase polymerase chain reaction (RT-PCR) could be a good alternative. 3 In recent years, several reports described the use of a RT-PCR for Tg to speci¢cally detect thyroid cells in the peripheral blood of treated thyroid cancer patients. 3^9 However, other reports indicate that all subjects, including those without a thyroid, possess Tg transcripts in blood; 10, 11 this has been ascribed to ectopic expression of Tg in blood cells. 10 Alternative splicing, leading to Tg transcripts that are detected by some but missed by other PCR assays, cannot account for the di¡erences between these reports. 9 Other potential sources of variation between earlier reports are di¡erences in RNA source and extraction methods, use of DNase-I, storage conditions, normalization methods, etc. Here we report our e¡orts to con¢rm earlier reports.We set out to collect blood samples from
Subjects and methods

Patients
All patients previously treated for di¡erentiated thyroid carcinoma who visited the outpatient clinic of the Department of Endocrinology or the Department of Nuclear Medicine between March 21 and July 5 2001 were invited to participate in the study. All patients gave informed consent. Blood samples from 58 patients (nine men and 49 women, median age 48 years, range 20 -88 years) treated for follicular (nˆ16), papillary (nˆ21) or mixed follicular/papillary (nˆ18) thyroid carcinoma were collected. For three patients, the type of di¡erentiated thyroid carcinoma was unknown at the time of the study (see Table 1 ). As a positive control, blood was collected from two healthy, euthyroidic subjects. Fifty-seven patients had been treated by near-total thyroidectomy (median 4 years, range 1 month-53 years prior to this investigation), followed by 131 I treatment for ablation of thyroid remnants in 55 patients. Additional 131 I treatment (one to seven treatments) had been given in 18 patients. One patient was primarily treated by radioiodine as surgical treatment was not possible due to extensive disease. Blood was drawn during thyroxine suppression therapy in 36 patients, during thyroxine withdrawal for 131 I scintigraphy in 18 patients, and on both occasions in four patients. In nine patients, autoantibodies against Tg were present. On the basis of clinical, scintigraphic and biochemical (Tg measurements) evaluation, 40 patients were considered to be free of any normal or carcinomatous thyroid tissue at the time of the investigation. The most recent wholebody scan (median 3 months prior to the investigation) showed thyroid bed 131 I uptake in six patients, both thyroid bed uptake and uptake elsewhere in the neck in four patients, and distant metastases with or without regional uptake in six patients.
Blood samples and RNA preparation
Approximately 10 mL whole blood was collected in EDTA tubes and immediately transported to the laboratory on ice. Total RNA was isolated from 1Í5 mL of blood using the Qiagen RNeasy blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The rest of the blood was used for serum Tg and Tg autoantibody assays (see below).
Reverse transcription
Reverse transcription was performed using the Reverse Transcription System (Promega Benelux BV, Leiden, The Netherlands) according to the manufacturer's protocol. After annealing of random hexamers for 10 min at 208C, cDNA synthesis was performed for 60 min at 428C, followed by an enzyme inactivation step for 5 min at 958C.
Real-time polymerase chain reaction assays
All PCRs were carried out using Taqman Universal PCR master mix (PE Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) with 500 nmol/ L of each primer and 100 nmol/ L of probe in a ¢nal volume of 25 mL. The Tg forward primer was 5'-GTG CCA ACG GCA GTG AAG t-3', the reverse primer 5'-TCT GCT GTT TCT GTA GCT GAC AAA-3', and the probe was 5'-FAM-5'ACA GAC AAG CCA CAG GCC GTC CT-TAMRA-3' as described earlier. 6 These were designed intron-spanning using the Primer-Express software package version 1Í5 (PE Applied Biosystems). b-Actin was ampli¢ed using the Pre-Developed Assay Reagents Taqman RT-PCR assay (PE Applied Biosystems). Ampli¢cations, with activation/denaturation at 958C for 10 min, and 45 cycles of 15 s at 958C (melting) and 60 s at 608C (annealing and elongation), were performed on an ABI Prism 7700 Sequence detection system (PE Applied Biosystems).
Quanti cation
Standards, consisting of bp 76 to 2110 of the Tg sequence cloned into pcDNA3 were obtained from Dr C Ris-Stalpers from the Amsterdam Medical Center, Amsterdam, The Netherlands. b-Actin standards were obtained from Dr J de Kok, from the University Medical Center Nijmegen, Nijmegen, The Netherlands. Standards were quanti¢ed spectrophotometrically and kept at a stock concentration of 10 7 molecules/mL and used at serial dilutions of 10 6 to 10 molecules/PCR reaction. All unknown samples were quanti¢ed against the Tg and b-actin standards in duplicate reactions from a single cDNA preparation in consecutive runs. The runs included two no-template controls, a calibration curve in duplicate, and unknowns.
Other assays
Serum Tg protein levels were determined using the Elsa-hTg immuno -radiometric assay from CIS Bio International (Schering Nederland, Weesp, The Netherlands). The assay has a detection limit of 0Í7 pmol/L, a clinical cut-o¡ of 3 pmol/L and an intraand inter-assay coe¤cient of variation (CV) of 6Í6 and 8Í0%, respectively. Autoantibodies against Tg were determined by a clinically validated in-house assay employing polyethyleneglycol precipitation using 125 I-Tg and a positive control using rabbit-anti-human Tg IgG (Byk Sangtec, Zwanenburg, The Netherlands). 
Statistics
Statistical analyses were carried out using SPSS 10.0.5 software (SPSS Benelux BV, Gorinchem, The Netherlands). To assess associations of Tg mRNA levels with other factors, patients were dichotomized for levels below or above the median. Pearson's chi-square was computed to test the hypothesis that cross-tabulated variables were independent.
Results
Thyroglobulin real-time reverse-transcriptase polymerase chain reaction characteristics
No-template controls were negative up to 45 cycles of ampli¢cation (results not shown). Both the Tg and the b-actin quantitative RT-PCR assay proved linear over a wide range of transcripts (see Fig. 1 ). As the Tg mRNA assay was somewhat less e¤cient, and both standard curves were thus not parallel, calibration curves were used for both assays and Tg and b-actin mRNA levels were calculated separately. The so-called delta-Ct method could have been used only if calibration curves were parallel.
Thyroglobulin mRNA expression levels in peripheral blood from patients
All peripheral blood samples from patients were positive for Tg mRNA (see Table 1 ). Levels ranged from 3Í5610 74 to 7Í9610 73 (median 1¢4610 73 ) Tg/bactin ratios (see Fig. 2 ). For Tg and b-actin, the intraassay variations were 24% and 6%, respectively, for the patients' samples. For Tg, intra-assay variations varied from 30% at low (500 copies/reaction), 15% at medium (1800 copies/reaction) to 8% at high (5000 copies/reaction) Tg levels. The two healthy controls exhibited similar levels, 8Í9610 74 and 1Í3610 73 , of Tg/b-actin. Tg mRNA levels did not di¡er between serum Tg negative and Tg positive patients (Pˆ0Í581, see Fig. 3 ). To compare the expression levels between di¡erent categories, patients were dichotomized in two groups based on the median Tg/b-actin level of 1Í4610 73 , i.e. low Tg or high Tg expression. No di¡erences in the number of patients with high or low Tg/bactin ratios (Pˆ0Í871) were found between patients considered to be free of any normal or carcinomatous thyroid tissue at the time of the investigation, patients with thyroid bed 131 I uptake on whole-body scan, both thyroid bed uptake and uptake elsewhere in the neck, or distant uptake (see Table 2 ). Tg expression levels did not di¡er (Pˆ0Í872) between the di¡erent histological subtypes (see Table 3 ). In contrast to an earlier report, 12 the quantitative detection of Tg expression was also non-informative with respect to disease status (Pˆ0Í332) in patients with papillary thyroid carcinoma (see Table 4 ).
Discussion
Here, we show that the quantitative assay for Tg mRNA concentrations in peripheral blood of patients treated for di¡erentiated thyroid carcinoma has limited clinical value. All subjects tested were found to express Tg mRNA in blood samples. These results concur with those of some recent papers, 10, 11 but are in sharp contrast to others. 3^9 In contrast to a recent report, 12 carcinomas Tg expression did not concur with clinical status. The use of real-time quantitative RT-PCR 6 precludes the sensitivity and quanti¢cation problems associated with end-point assays. 8 Furthermore, the use of an appropriate internal control to adjust for RNA degradation and PCR e¤ciency has been advocated. 11 In the present study, both issues have been addressed by applying a real-time quantitative Taqman RT-PCR for Tg and b-actin. Earlier studies showed that using similar amounts of whole blood, as we used here, would be su¤cient to detect circulating thyroid cells. 6, 9, 10, 13 Thus, no enrichment method would seem to be necessary to detect circulating cells. Indeed, Tg mRNAs were detectable in all samples tested. In spite of the aforementioned precautions, we were not able to con¢rm the positive reports on the use of Tg RT-PCR to detect the presence of circulating thyroid cells. The assay employed here uses primers in exon 3 and exon 4 of theTg sequence. 6, 13 Signi¢cant di¡erences in Tg expression levels are reported between patients with no uptake on whole-body iodine scan and patients with uptake, in the paper that originally described this particular assay. 6, 13 Thus, di¡erences between primer pairs used, with concomitant di¡erences in splice variant detection rates, 9 cannot account for the di¡erence in results between the paper of Ringel 6 and the present paper.
Conclusion
In conclusion, recent reports on illegitimate Tg transcription in peripheral blood cells might account for the Tg mRNAs found in controls and patients without evidence of residual thyroid tissue and/or recurrent disease, as described in the present paper. Recent positive reports describing the use of real-time quantitative RT-PCR to detect Tg mRNA as a valuable tool in the follow-up of patients treated for thyroid cancer could not be con¢rmed.
